



**STERN CONSULT**

International Clinical Research Consulting

---

# CV Angelika C. Stern





# CV Angelika C. Stern

- \* PhD in Immunology
  - Basel University
- \* Post Doctorate
  - Basel University (DFG Grant)
- \* 3 years Head of Laboratory for Bone Marrow Transplantation
  - University Hospital, Bern
- \* 9 years Clinical Expert at Sandoz, Basel
  - Responsible for numerous immunological and oncological projects
  - Registration of Leucomax (e.coli GM-CSF) in Europe





# CV Angelika C. Stern

- \* 3 years International Medical Manager for Neupogen
  - Roche, Basel
- \* Since 1998 Independent Consultant
  - Working on all aspects of clinical development





# Consultancy Activities

## \* Emerging Biotech Companies

- Project management
- Clinical development plans
- Organizing phase I studies
- Organizing proof-of-concept studies
  - \* NCEs, monoclonal antibodies, vaccines, gene therapy





# Consultancy Activities

## \* Hesperion

- Phase I: advanced solid tumors
- Phase II: prostate, breast, gastric, pancreatic cancer; NHL; glioblastoma; RCC
- Phase III: RCC
- Business development





# Employment Activities

## \* Roche

- Leading the medical team for Neupogen®, reporting to the Amgen-Roche joint development team
- Management of clinical trials phase III and phase IV
- All types of solid and haematological tumors with and without BMT





# Employment Activities

## \* Roche

- Coordination of international study centers and groups
- Clinical trials reporting, auditing
- Scientific lectures at national meetings in Europe, Middle- and Far East





# Employment Activities

## \* Sandoz

- Development (phase I – phase III) and registration of GM-CSF (Leucomax®) in cooperation with Schering-Plough Ltd.
- NHL; aplastic anemia; BMT; SCLC; testicular, breast, ovarian cancer
- Life cycle management after registration





# Employment Activities

## \* Sandoz

- Clinical development of anti-viral monoclonal antibodies, lipid A analogue as cytokine stimulator
- Novel antirheumatic, oncological, dermatological and anti-infectious agents from phase I - phase IV
- International lecturing at conferences and launch meetings

